Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.
Profitability
This table compares Ascendis Pharma A/S and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ascendis Pharma A/S | 70.99% | 32.54% | 7.71% |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
Insider and Institutional Ownership
77.7% of Taysha Gene Therapies shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Ascendis Pharma A/S and Taysha Gene Therapies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ascendis Pharma A/S | $814.57 million | 17.25 | -$258.00 million | $12.89 | 17.47 |
| Taysha Gene Therapies | $5.49 million | 215.04 | -$109.00 million | ($0.42) | -8.62 |
Taysha Gene Therapies has lower revenue, but higher earnings than Ascendis Pharma A/S. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Ascendis Pharma A/S and Taysha Gene Therapies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ascendis Pharma A/S | 0 | 1 | 18 | 1 | 3.00 |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
Ascendis Pharma A/S presently has a consensus price target of $309.26, suggesting a potential upside of 37.30%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 252.74%. Given Taysha Gene Therapies’ higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Ascendis Pharma A/S.
Risk & Volatility
Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
Summary
Ascendis Pharma A/S beats Taysha Gene Therapies on 8 of the 14 factors compared between the two stocks.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
